Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT), a global leader in analytical instrumentation and laboratory technologies, provides critical solutions for pharmaceutical development, food safety testing, and environmental monitoring. This dedicated news hub aggregates official announcements, financial disclosures, and strategic updates directly impacting the company's market position and technological advancements.
Investors and industry professionals will find curated updates including quarterly earnings reports, product innovation announcements, executive leadership changes, and regulatory developments. Our repository ensures timely access to filings, partnership agreements, and scientific breakthroughs related to Waters' chromatography systems, mass spectrometry platforms, and thermal analysis instruments.
Key content categories include financial performance updates, new product launches, research collaborations, and operational expansions. Bookmark this page to monitor developments affecting Waters' role in life sciences R&D, quality assurance protocols, and laboratory informatics solutions across 100+ countries.
Waters (NYSE: WAT) has announced its Q2 2024 earnings conference call will take place on July 31, 2024, at 8:00 a.m. Eastern Time. The event will be webcast live on the Waters Investor Relations website, with a replay available until August 28, 2024. Waters , a leader in analytical instruments and software, continues to serve diverse industries such as life sciences, materials, food, and environmental sciences. The company operates in 35 countries, with a workforce of approximately 7,700 employees and 15 manufacturing facilities worldwide.
Waters has unveiled its new Xevo MRT Mass Spectrometer at the 72nd ASMS Conference. This next-generation instrument employs advanced multi-reflecting time-of-flight technology, offering up to 6x higher resolution and 2x mass accuracy compared to competitors. The Xevo MRT enables faster processing of large sample cohorts, essential for biomedical and epidemiology research. It delivers high resolution, speed, and sensitivity, ensuring reliable data for complex disease studies. The system is compatible with Waters' software, columns, and third-party applications, facilitating comprehensive workflows for metabolomic and lipidomic research. The Xevo MRT will be available for shipment in the second half of 2024.
Waters (NYSE: WAT) has become the first liquid chromatography column provider to receive ACT™ Ecolabel Certification from My Green Lab for 42 of its columns. This certification independently validates the environmental impact of the manufacturing, use, packaging, and disposal of Waters' products. Waters supplies its columns to a wide range of laboratories globally, across various scientific fields. The ACT Ecolabel helps scientists and procurement professionals make sustainable choices without compromising on performance. Waters has a long-standing reputation for quality in LC column chemistries, with innovations like MaxPeak™ Premier High-Performance Surfaces and CORTECS™ Solid Core Particles enhancing lab efficiency. They continue to improve sustainability by using recycled packaging materials and reducing packaging size. This certification underscores Waters' commitment to sustainability and provides a competitive edge in the market.
Waters (NYSE: WAT) will present at the Jefferies 2024 Healthcare Conference. President and CEO Udit Batra Ph.D. will participate in a fireside chat on June 5th, 2024. Waters , a global leader in analytical instruments and software, operates in 35 countries with products available in over 100 countries.
WAT Medical introduces ObeEnd, a revolutionary weight management wristband supported by clinical evidence. The device aims to address the global obesity epidemic by providing a drug-free, effective solution. ObeEnd utilizes neuromodulation technology to reduce caloric intake and enhance post-exercise recovery, showing promising results in clinical studies. The groundbreaking innovation marks a major milestone in the field of weight management.
Waters announced the release of the ACQUITY QDa II Mass Detector, a cost-effective, energy-efficient instrument that enhances compound identification through mass analysis. The new detector offers a 20% increase in mass range, up to 70% lower energy consumption, and is recognized for sustainability by My Green Lab.
Waters (NYSE: WAT) reported first-quarter 2024 financial results with sales of $637 million, a 7% decline, but at the high end of guidance. GAAP EPS was $1.72, well above guidance, with non-GAAP EPS of $2.21. Operational excellence led to gross margin expansion. Full-year guidance maintained for -0.5% to +1.5% organic constant currency sales growth and non-GAAP EPS of $11.75 to $12.05.
FAQ
What is the current stock price of Waters (WAT)?
What is the market cap of Waters (WAT)?
